Neue Suche | Kongressdetail
mail
Druckansicht
 
 

3rd TIGIT Axis Therapies

Evvnt Promotion / evvnt
-
07.12.2022 - 08.12.2022  Virtual Event, USA
Time: 8:00 am to 5:00 pm
 
Kongressthemen
As immuno-oncology drug development transforms cancer treatment paradigms, preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.
Wissenschaftliche Fach-Gesellschaft
Hanson Wade
Anmerkungen
Speakers: Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies, David Wald, Associate Professor, Case Western Reserve University, Leonie Meima, Vice President Business Development, Coherus Biosciences
 

Anfragen und Anmeldung:

https://go.evvnt.com/1234464-2?pid=4832
Frau Ellie Saunders
 
Kategorien
Onkologie
Sprache
Englisch
Kongressgebühr
Conference Only - Industry Pricing - On the Day : USD 2299.00, Conference Only - Academic Pricing - On the Day: USD 2099.00, Conference Only - Service and Solution Provider Pricing - On the Day: USD 2799.00
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

Center of ExcellenceAMREF - African Medical and Research FoundationEuropean Public Health Association (EUPHA)Anästhesie in Entwicklungsländern e. V.Hilfswerk AustriaÖsterreichische Akademie der ÄrzteOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation AGEM - Arbeitsgemeinschaft Ethnologie und Medizin